<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01650181</url>
  </required_header>
  <id_info>
    <org_study_id>GAS-399-11/11/1</org_study_id>
    <nct_id>NCT01650181</nct_id>
  </id_info>
  <brief_title>Effects of Siliphos-Selenium-Methionine-Alpha Lipoic Acid in Patients With Fatty Liver and Non-alcoholic Steatohepatitis</brief_title>
  <official_title>Biochemical and Echosonographic Impacts Using Siliphos-Selenium-Methionine-Alpha Lipoic Acid + Metformin Versus Metformin in Patients With Fatty Liver and Steatohepatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-alcoholic steatohepatitis represents 10 - 15% total cases of hepatic cirrhosis. In the
      upcoming years, the economic burden of this disease will increase and will mean an important
      problem for our health system due to obesity epidemic.

      There are several treatments for non-alcoholic steatohepatitis; however, none of them have
      overcome a healthy lifestyle including diet, exercise and some drugs related with insulin
      metabolism.

      There after, using hepatoprotective drugs and antioxidants have been recommended as an
      eligible therapy to reduce the progression from fatty liver to steatohepatitis and cirrhosis.
      Being this approach not only an experimental item yet but also an unavoidable reality.

      The purpose of this randomized controlled study is explore the effects of
      siliphos-selenium-methionine-alpha lipoic acid + metformin versus metformin in patients with
      fatty liver and non-alcoholic steatohepatitis about biochemical and echosonographic
      parameters.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Impact on biochemical and echosonographic parameters</measure>
    <time_frame>6 months</time_frame>
    <description>Identify and measure if patients with metabolic syndrome with NALFD under Siliphos (140mg) + Selenium (15mcg) - Methionine (3mg) + Alfa lipoic acid (200mg) treatment added to conventional therapy improves echosonographic pattern measure accord bright scale and biochemical parameters like LFT´s compared with conventional therapy alone (metformin + diet + exercise).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identify changes in anthropometric parameters</measure>
    <time_frame>6 months</time_frame>
    <description>Identify and measure changes in anthropometrics parameters of metabolic syndrome like BMI, fasting glucose, lipid profile, arterial pressure, abdominal perimeter, waist index.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Liver Disease</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients treated with diet, exercise and metformin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Suplement</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients treated with diet, exercise and metformin plus Siliphos (140mg) + Selenium (15mcg) -Methionine 3mg + Alpha Lipoic Acid (200mg).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Patients with Steatohepatitis treated with diet, exercise and metformin</description>
    <arm_group_label>Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Siliphos+ Selenium - Methionine + Alpha Lipoic Acid</intervention_name>
    <description>Patients with Steatohepatitis treated with diet, exercise, metformin and Siliphos (140mg) + Selenium (15 mcg) - Methionine (3mg) + Alpha Lipoic Acid (200mg), two tablets BID</description>
    <arm_group_label>Suplement</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Siliphos+ Selenium - Methionine + Alpha Lipoic Acid</intervention_name>
    <description>Patients with fatty liver treated with diet, exercise, metformin and Siliphos (140mg) + Selenium (15 mcg) - Methionine (3mg) + Alpha Lipoic Acid (200mg), two tablets BID</description>
    <arm_group_label>Suplement</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Patients with fatty liver treated with diet, exercise and metformin</description>
    <arm_group_label>Metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with Metabolic Syndrome according to ATP III Criteria

          -  Non smokers

          -  Without intake of vitamins or herbal medicine for at least one month

          -  Without uncontrolled glycemic levels

          -  Compatible ultrasound and/or histological report

        Exclusion Criteria:

          -  Alcohol ingest &gt; 50 gr weekly or chronic alcoholism

          -  Creatine serum &gt; 2 mg/dL

          -  Potassium serum &gt; 5.5 mEq/L

          -  Allergic to metformin or any components of the study

          -  Pregnancy

          -  Anomalies of blood coagulation or liver anatomic

          -  Patients with diseases and/or treatment that cause fatty liver or steatohepatitis

          -  Body weight change &gt; 10% in the last 5 weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aldo Torre Delgadillo, M.D., M. Sc.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán</name>
      <address>
        <city>Mexico City</city>
        <zip>14000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2012</study_first_submitted>
  <study_first_submitted_qc>July 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2012</study_first_posted>
  <last_update_submitted>August 18, 2014</last_update_submitted>
  <last_update_submitted_qc>August 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</investigator_affiliation>
    <investigator_full_name>ALDO TORRE DELGADILLO</investigator_full_name>
    <investigator_title>M.D. Science Master</investigator_title>
  </responsible_party>
  <keyword>nafld, nash, fatty liver</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Selenium</mesh_term>
    <mesh_term>Thioctic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

